Weinblatt, M. E., Baranauskaite, A., Niebrzydowski, J., Dokoupilova, E., Zielinska, A., Jaworski, J., . . . Tseluyko, V. (2017). Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis. Arthritis Rheumatol.
Chicago Style CitationWeinblatt, Michael E., et al. "Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis." Arthritis Rheumatol 2017.
Cita MLAWeinblatt, Michael E., et al. "Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis." Arthritis Rheumatol 2017.
Atenció: Aquestes cites poden no estar 100% correctes.